Tanvex BioPharma, Inc.

NT$27.85As of Sun 8 Nov 2026, 12:00 UTC
TWSE:6541Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (23.93%)
Div yield —
ROE (29.78%)
Biotechnology
Beta (5Y) 0.23
PE TTM —
TSR TTM (50.36%)
Mkt cap NT$7.380B
ROIC (13.26%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$31
10.27%
(56.56%)
Hold 11|5|11|7|8
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.32
0.32
0.36
0.34
5.26%
10.95%
17.32%
8.87%
RevenueNT$M
601.7
624.8
616.6
609.8
15.36%
18.79%
14.24%
7.36%
Peers (US$222.9M)
Cap (US$)
PE
229.6M
14.11x
Capital
TTM
5Y
10Y
Leveragex
1.329
(1.219)
(0.833)
EBIT/Intx
0.927
0.189
0.212
Own earn%
(22.21)
(30.15)
(20.57)
Sh yield%
33.68
55.69
54.51
Owners
Insiders/Inst%
2.26
83.72
Short interest%
4.47
SBC / revenue%
4.09
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
4–11
$1 testx
7.1
Incr. ROIC%
−1